Literature DB >> 10636531

Heart failure in arrhythmogenic right ventricular dysplasia-cardiomyopathy.

S Peters1, H Peters, L Thierfelder.   

Abstract

UNLABELLED: Sudden arrhythmic death and heart failure are essential factors influencing the prognosis of arrhythmogenic right ventricular dysplasia-cardiomyopathy. Heart failure is a rare, but often lethargic event although little is known about morphology, time course and non-invasive predictors.
METHOD: In a retrospective study of a consecutive cohort of 121 patients with ARVD over a follow-up period of up to 12 years morphological features of heart failure, time course from the initial diagnosis and standard 12-lead ECG as a non-invasive predictor of developing heart failure were analysed.
RESULTS: Heart failure occurred in 13 patients (11%) with isolated right ventricular dilatation and loss of function in 10 cases (77%) and biventricular failure in three cases (23%). Patients developed NYHA class IV in four cases, class III-IV in two cases and class II in seven cases in 4-8 years. In standard ECG of 12 patients (92%) complete right bundle branch block was present at the time of initial diagnosis (n=6) or in a time interval of 4 years (n=6). Morphological distinction of isolated right and biventricular heart failure could be achieved not only by imaging techniques such as echocardiography or cardioangiography, but also by standard ECG with right atrial hypertrophy and an increased mean precordial QRS dispersion of 47.1+/-18.9 ms in cases of right heart failure and biatrial hypertrophy and a reduced precordial QRS dispersion of 33.0+/-23.1 ms in cases of biventricular heart failure.
CONCLUSIONS: Heart failure in ARVD consists of isolated right ventricular and biventricular dilatation and pump failure in a time course of 4-8 years after developing complete right bundle branch block as a strong non-invasive predictor from standard 12-lead ECG.

Entities:  

Mesh:

Year:  1999        PMID: 10636531     DOI: 10.1016/s0167-5273(99)00143-6

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  Role of cardiac imaging evaluation of patients with documented or suspected ventricular arrhythmias.

Authors:  Naveen Jonnalagadda; Aditya Jain; Hugh Calkins; Harikrishna Tandri
Journal:  J Nucl Cardiol       Date:  2010 Jan-Feb       Impact factor: 5.952

2.  Differential expression of the cardiac ryanodine receptor in normal and arrhythmogenic right ventricular cardiomyopathy canine hearts.

Authors:  Kathryn M Meurs; Veronique A Lacombe; Keith Dryburgh; Philip R Fox; Peter R Reiser; Mark D Kittleson
Journal:  Hum Genet       Date:  2006-05-30       Impact factor: 4.132

3.  Diagnosis of arrhythmogenic right ventricular dysplasia-cardiomyopathy: value of standard ECG revisited.

Authors:  Stefan Peters; Martina Trümmel
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-07       Impact factor: 1.468

Review 4.  Noninvasive risk stratification in arrhythmogenic right ventricular cardiomyopathy.

Authors:  Pietro Turrini; Domenico Corrado; Cristina Basso; Andrea Nava; Gaetano Thiene
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-04       Impact factor: 1.468

5.  QRS fragmentation in patients with arrhythmogenic right ventricular cardiomyopathy and complete right bundle branch block: a risk stratification.

Authors:  Stefan Peters
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-09

6.  Heart transplantation outcomes in arrhythmogenic right ventricular cardiomyopathy: a contemporary national analysis.

Authors:  Katherine Giuliano; Paul Scheel; Eric Etchill; Charles D Fraser; Alejandro Suarez-Pierre; Steven Hsu; Ilan S Wittstein; Edward K Kasper; Roberta Florido; Harikrishna Tandri; Hugh Calkins; Chun W Choi; Kavita Sharma; Ahmet Kilic; Nisha A Gilotra
Journal:  ESC Heart Fail       Date:  2022-02-08

Review 7.  Arrhythmogenic Cardiomyopathy: Exercise Pitfalls, Role of Connexin-43, and Moving beyond Antiarrhythmics.

Authors:  Isabella Leite Coscarella; Maicon Landim-Vieira; José Renato Pinto; Stephen P Chelko
Journal:  Int J Mol Sci       Date:  2022-08-06       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.